Original language | English (US) |
---|---|
Pages (from-to) | 2013-2018.e7 |
Journal | Gastroenterology |
Volume | 159 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2020 |
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Defining Endpoints and Biomarkers in Inflammatory Bowel Disease : Moving the Needle Through Clinical Trial Design. / IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group.
In: Gastroenterology, Vol. 159, No. 6, 12.2020, p. 2013-2018.e7.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Defining Endpoints and Biomarkers in Inflammatory Bowel Disease
T2 - Moving the Needle Through Clinical Trial Design
AU - IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group
AU - Abreu, Maria T.
AU - Sandborn, William J.
AU - Cataldi, Fabio
AU - D'Haens, Geert
AU - Feagan, Brian G.
AU - Hanauer, Stephen
AU - Jairath, Vipul
AU - Lakatos, Peter
AU - Leptak, Christopher
AU - McGovern, Dermot
AU - Mulberg, Andrew
AU - Panes, Julian
AU - Parikh, Asit
AU - Peyrin-Biroulet, Laurent
AU - Reinisch, Walter
AU - Riddell, Robert
AU - Rubin, David
AU - Sands, Bruce
AU - Spleiss, Johannes
AU - Strauss, Richard
AU - Tole, Swati
AU - Tomaino, Juli
N1 - Funding Information: The IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group represents expert speakers and panelists who participated in the meeting and who also served as authors in the development of the Meeting Summary. Members are as follows: Fabio Cataldi, AbbVie Inc; Geert D'Haens, Amsterdam UMC/AMC; Brian G. Feagan, University of Western Ontario, Robarts Clinical Trials, Inc; Stephen Hanauer, Northwestern University; Vipul Jairath, University of Western Ontario, Robarts Clinical Trials, Inc; Peter Lakatos, McGill University Health Center; Christopher Leptak, US Food and Drug Administration; Dermot McGovern, Cedars-Sinai Medical Center; Andrew Mulberg, Amicus Therapeutics, Inc; Julian Panes, Hospital Clinic Barcelona, IDIBAPS, CIBERehd; Asit Parikh, Takeda Pharmaceuticals; Laurent Peyrin-Biroulet, CHU de Nancy; Walter Reinisch, Medical University of Vienna; Robert Riddell, Mount Sinai Hospital; David Rubin, University of Chicago; Bruce Sands, Icahn School of Medicine at Mount Sinai; Johannes Spleiss, Tillotts Pharma AG; Richard Strauss, Janssen Research Development; Swati Tole, Genentech Inc; Juli Tomaino, US Food and Drug Administration. Maria T. Abreu and William J. Sandborn drafted the manuscript, and all authors critically reviewed, contributed important intellectual content, and approved the final draft for submission.
PY - 2020/12
Y1 - 2020/12
UR - http://www.scopus.com/inward/record.url?scp=85097435261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097435261&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2020.07.064
DO - 10.1053/j.gastro.2020.07.064
M3 - Article
C2 - 32961246
AN - SCOPUS:85097435261
VL - 159
SP - 2013-2018.e7
JO - Gastroenterology
JF - Gastroenterology
SN - 0016-5085
IS - 6
ER -